Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06207305 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
A Phase 1 study of Metastatic Appendiceal Adenocarcinoma and Intraperitoneal Paclitaxel, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06207305 is a Phase 1 study of Metastatic Appendiceal Adenocarcinoma and Intraperitoneal Paclitaxel that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06207305, a Phase 1 study of Metastatic Appendiceal Adenocarcinoma and Intraperitoneal Paclitaxel, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Dexamethasone
- DRUG Diphenhydramine
- DRUG Famotidine
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2028-01-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06207305
The ClinicalTrials.gov registry entry for NCT06207305 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Appendiceal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Paclitaxel is the first listed.
NCT06207305 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06207305 about?
NCT06207305 is a clinical study titled "A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma". To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
What is the current status of trial NCT06207305?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2024-01-30. Estimated completion is 2028-01-02.
What conditions does trial NCT06207305 study?
This clinical trial studies the following conditions: Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel.
What interventions are being tested in trial NCT06207305?
The interventions under investigation include: Paclitaxel (DRUG), Dexamethasone (DRUG), Diphenhydramine (DRUG), Famotidine (DRUG).
Who is sponsoring clinical trial NCT06207305?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06207305 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.